Smith & Nephew plc (NYSE:SNN) is Clark Estates Inc. NY’s 5th Largest Position

Clark Estates Inc. NY lowered its holdings in Smith & Nephew plc (NYSE:SNN) by 8.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 685,000 shares of the medical equipment provider’s stock after selling 65,000 shares during the quarter. Smith & Nephew accounts for 4.0% of Clark Estates Inc. NY’s holdings, making the stock its 5th largest holding. Clark Estates Inc. NY’s holdings in Smith & Nephew were worth $21,331,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of SNN. Townsquare Capital LLC raised its stake in shares of Smith & Nephew by 5.4% in the 3rd quarter. Townsquare Capital LLC now owns 14,759 shares of the medical equipment provider’s stock valued at $460,000 after acquiring an additional 761 shares during the period. Cerity Partners LLC increased its holdings in Smith & Nephew by 31.5% in the 3rd quarter. Cerity Partners LLC now owns 19,001 shares of the medical equipment provider’s stock valued at $592,000 after purchasing an additional 4,552 shares during the last quarter. Citigroup Inc. raised its position in Smith & Nephew by 18.5% in the third quarter. Citigroup Inc. now owns 119,215 shares of the medical equipment provider’s stock valued at $3,712,000 after purchasing an additional 18,630 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Smith & Nephew by 29.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 27,199 shares of the medical equipment provider’s stock worth $847,000 after purchasing an additional 6,164 shares in the last quarter. Finally, Pathstone Holdings LLC lifted its stake in Smith & Nephew by 14.8% during the third quarter. Pathstone Holdings LLC now owns 48,903 shares of the medical equipment provider’s stock worth $1,523,000 after purchasing an additional 6,317 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SNN shares. Berenberg Bank downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. StockNews.com downgraded Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold”.

Smith & Nephew Trading Up 0.6 %

SNN stock opened at $25.30 on Wednesday. The business’s 50-day moving average is $27.88 and its two-hundred day moving average is $27.90. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. Smith & Nephew plc has a 1 year low of $23.65 and a 1 year high of $31.72.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.